Elk Creek Partners LLC lifted its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 5.2% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 591,869 shares of the biotechnology company’s stock after buying an additional 29,347 shares during the quarter. Sarepta Therapeutics makes up approximately 1.3% of Elk Creek Partners LLC’s portfolio, making the stock its 18th biggest position. Elk Creek Partners LLC owned 1.08% of Sarepta Therapeutics worth $19,952,000 at the end of the most recent reporting period.
Several other institutional investors also recently made changes to their positions in SRPT. Prentiss Smith & Co. Inc. lifted its stake in Sarepta Therapeutics by 772.2% during the second quarter. Prentiss Smith & Co. Inc. now owns 3,576 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 3,166 shares during the last quarter. Ameritas Investment Partners Inc. purchased a new stake in Sarepta Therapeutics during the first quarter worth approximately $127,000. PNC Financial Services Group Inc. lifted its stake in Sarepta Therapeutics by 150.1% during the first quarter. PNC Financial Services Group Inc. now owns 4,666 shares of the biotechnology company’s stock worth $138,000 after purchasing an additional 2,800 shares during the last quarter. Edge Wealth Management LLC purchased a new stake in Sarepta Therapeutics during the second quarter worth approximately $175,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in Sarepta Therapeutics during the first quarter worth approximately $209,000. 65.43% of the stock is owned by institutional investors and hedge funds.
SRPT has been the subject of several recent analyst reports. Vetr cut Sarepta Therapeutics from a “buy” rating to a “hold” rating and set a $36.86 target price for the company. in a research note on Monday, May 22nd. Nomura restated a “buy” rating and set a $84.00 target price on shares of Sarepta Therapeutics in a research note on Tuesday, May 23rd. ValuEngine upgraded Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Oppenheimer Holdings, Inc. set a $76.00 target price on Sarepta Therapeutics and gave the stock a “buy” rating in a research note on Thursday, June 8th. Finally, Royal Bank Of Canada restated a “buy” rating and set a $60.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, June 22nd. Nine equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $62.31.
In other news, CEO Douglas S. Ingram acquired 47,058 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, July 27th. The stock was purchased at an average price of $42.50 per share, with a total value of $1,999,965.00. Following the completion of the transaction, the chief executive officer now owns 382,058 shares in the company, valued at $16,237,465. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Sandesh Mahatme sold 50,000 shares of Sarepta Therapeutics stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $41.00, for a total value of $2,050,000.00. Following the sale, the chief financial officer now directly owns 41,736 shares of the company’s stock, valued at approximately $1,711,176. The disclosure for this sale can be found here. In the last three months, insiders have sold 78,056 shares of company stock valued at $3,224,208. Insiders own 9.60% of the company’s stock.
Sarepta Therapeutics, Inc. (SRPT) traded up 0.69% during trading on Friday, hitting $46.51. The stock had a trading volume of 3,466,205 shares. The firm’s 50 day moving average is $39.72 and its 200 day moving average is $34.68. The firm’s market cap is $2.99 billion. Sarepta Therapeutics, Inc. has a 1-year low of $26.26 and a 1-year high of $63.73.
Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.46. The firm had revenue of $35.01 million for the quarter, compared to analyst estimates of $22.52 million. Sarepta Therapeutics’s revenue for the quarter was up 350000.0% on a year-over-year basis. During the same period in the previous year, the business posted ($1.19) EPS. On average, analysts anticipate that Sarepta Therapeutics, Inc. will post ($1.23) earnings per share for the current year.
Sarepta Therapeutics Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT).
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.